In liver hepatocellular carcinoma (LIHC), the positive correlation between LRFN4 and immunotherapy targets such as PDCD1 and CTLA4 implies that LRFN4 can impact the interaction between immune cells and tumor cells, potentially modulating the efficacy of immune checkpoint blockade (ICB) therapy. Here, CTLA4 is linked to neoplasm.